3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Bevacizumab: a new way of doing business. Part 2

      ,
      Eye
      Springer Nature

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.

          To compare the efficacy and safety of bevacizumab versus ranibizumab when administered according to a treat-and-extend protocol for the treatment of neovascular age-related macular degeneration (AMD).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome

            Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group

              Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group
                Bookmark

                Author and article information

                Journal
                Eye
                Eye
                Springer Nature
                0950-222X
                1476-5454
                November 27 2018
                Article
                10.1038/s41433-018-0281-2
                6461904
                30482906
                5d7d8147-9c3d-40a0-9fc4-190b5e7d2d42
                © 2018

                http://www.springer.com/tdm

                History

                Comments

                Comment on this article